Overview
BLLN market data
Price History
BLLN price chart
Valuation & Profitability
- P/E (TTM)
- 123.44 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $0.35 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.09 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 9.5% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $61.96 – $150.44 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $4.7B · P/B 7.80 · P/S 11.71.
Company News
BillionToOne shares are trading lower after the company reported mixed Q3 financial results. Also, BTIG lowered its price target on the stock from $142 to $130.Benzinga · Aug 6, 2026, 11:46 AM
BTIG Maintains Buy on BillionToOne, Lowers Price Target to $130Benzinga · Aug 6, 2026, 9:51 AM
BillionToOne Stock (BLLN) Falls After Hours: Here's What's Driving the MoveBenzinga · Aug 6, 2026, 6:01 AM
BillionToOne shares are trading lower after the company reported mixed Q3 financial results.Benzinga · Aug 5, 2026, 8:45 PM
8-K filing — BillionToOne, Inc. (BLLN)SEC EDGAR · Aug 5, 2026, 8:25 PM
BillionToOne Affirms FY2026 Sales Guidance of $450.000M-$465.000M vs $456.440M EstBenzinga · Aug 5, 2026, 8:14 PM
BillionToOne Q3 EPS $0.15 Misses $0.19 Estimate, Sales $109.400M Beat $109.365M EstimateBenzinga · Aug 5, 2026, 8:13 PM
Guggenheim Initiates Coverage On BillionToOne with Buy Rating, Raises Price Target to $125Benzinga · Jun 29, 2026, 2:00 PM
Jim Cramer: Design Therapeutics Is 'Pure Spec,' Buy This Health Care StockBenzinga · May 15, 2026, 11:50 AM